Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

BACKGROUND: Biosimilars must meet stringent regulatory requirements, both at the time of authorization and during their lifecycle. Yet it has been suggested that divergence in quality attributes over time may lead to clinically meaningful differences between two versions of a biologic. Therefore, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebbers, Hans C., Fehrmann, Bjørn, Ottosen, Mette, Hvorslev, Niels, Høier, Pia, Hwang, Jae-Woong, Chung, Jinhan, Lim, Hyoung Taek, Lee, Shinjung, Hong, Juyoung, Rezk, Mourad Farouk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113226/
https://www.ncbi.nlm.nih.gov/pubmed/31925703
http://dx.doi.org/10.1007/s40259-019-00402-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113226/
https://www.ncbi.nlm.nih.gov/pubmed/31925703
http://dx.doi.org/10.1007/s40259-019-00402-0

Ejemplares similares